Compare
Chemomab Therapeutics Ltd. vs NRX Pharmaceuticals, Inc. vs PMGC Holdings Inc. vs PRF Technologies Ltd.
| Latest fiscal year | Chemomab Therapeutics Ltd. CMMB | NRX Pharmaceuticals, Inc. NRXP | PMGC Holdings Inc. ELAB | PRF Technologies Ltd. PRFX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.45M | $590.1K | $17.0K |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | 65.1% (computed) | 31.4% | -311.8% (computed) |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/m | n/m |
| Net income | -$8.99M | -$28.62M | -$7.75M | -$5.02M |
| EPS (Diluted) | $0.018 | n/a | n/a | -$7.47 |
| Operating cash flow | -$11.13M | -$14.11M | -$5.93M | -$3.96M |
| Free cash flow | -$11.13M | n/a | -$6.38M | -$3.96M |
| Cash & equivalents | $7.56M | $7.80M | n/a | $3.12M |
| Total assets | $13.81M | $12.96M | $12.87M | $12.00M |
| Total liabilities | $1.48M | $28.89M | $5.03M | $2.71M |
| Shareholders' equity | $12.33M | -$15.94M | $7.84M | $8.54M |
| Return on year-end equity | -72.9% | n/a | -98.9% | -58.8% |
| Shares outstanding | n/a | 31.73M | 80.7K | 830.6K |
Revenue, most recent five fiscal years
| Fiscal year | Chemomab Therapeutics Ltd. | NRX Pharmaceuticals, Inc. | PMGC Holdings Inc. | PRF Technologies Ltd. |
|---|---|---|---|---|
| Latest | n/a | $1.45M Ended 2025-12-31 | $590.1K Ended 2025-12-31 | $17.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $1.71M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $766.3K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |